Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays

References

• Hoos A, Lewis JJ, and Brennan MF: Weichgewebssarkome—prognostische Faktoren und multimodale Therapie. Der Chirurg 71, 787–794, 2000. doi: 10.1007/s001040051137
   PubMed Web of Science ®Google Scholar
• Patrikidou A, Domont J, Cioffi A, and Le Cesne A: Treating soft tissue sarcomas with adjuvant chemotherapy. Curr Treat Options Oncol 12, 21–31, 2011.
   PubMed Web of Science ®Google Scholar
• Kaushal A and Citrin D: The role of radiation therapy in the management of sarcomas. Surg Clin North Am 88, 629–646, viii, 2008. doi: 10.1016/j.suc.2008.03.005
   PubMed Web of Science ®Google Scholar
• O'Brien GC, Cahill RA, Bouchier-Hayes DJ, and Redmond HP: Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma. Irish J Med Sci 175, 10–14, 2006.
   PubMed Web of Science ®Google Scholar
• Solomon LR, Cheesbrough JS, Bhargava R, Mitsides N, Heap M, et al.: Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis. Semin Dial 25, 233–238, 2012. doi: 10.1111/j.1525-139X.2011.00951.x
   PubMed Web of Science ®Google Scholar
• Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, et al.: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 112, 1585–1591, 2008. doi: 10.1002/cncr.23332
   PubMed Web of Science ®Google Scholar
• Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM, et al.: Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer 85, 389–395, 1999.
   PubMed Web of Science ®Google Scholar
• Pezzi CM, Pollock RE, Evans HL, Lorigan JG, Pezzi TA, et al.: Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg 211, 476–481, 1990.
   PubMed Web of Science ®Google Scholar
• Donato Di Paola E, and Nielsen OS: The EORTC soft tissue and bone sarcoma group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38 Suppl 4, S138–S141, 2002.
   PubMed Web of Science ®Google Scholar
• Nedea EA and DeLaney TF: Sarcoma and skin radiation oncology. Hematol Oncol Clin North Am 20, 401–429, 2006. doi: 10.1016/j.hoc.2006.01.017
   PubMed Web of Science ®Google Scholar
• Brodowicz T, Schwameis E, Widder J, Amann G, Wiltschke C, et al.: Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial. Sarcoma 4, 151–160, 2000. doi: 10.1080/13577140020025869
   PubMedGoogle Scholar
• Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, et al.: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19, 1238–1247, 2001.
   PubMed Web of Science ®Google Scholar
• Judson I, Verweij J, Gelderblom H, Hartmann JT, Schoffski P, et al.: Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 15, 415–423, 2014. doi: 10.1016/s1470-2045(14)70063-4
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, and Ewer MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97, 2869–2879, 2003. doi: 10.1002/cncr.11407
   PubMed Web of Science ®Google Scholar
• Burningham Z, Hashibe M, Spector L, and Schiffman JD: The epidemiology of sarcoma. Clin Sarcoma Res 2, 14, 2012. doi: 10.1186/2045-3329-2-14
   PubMedGoogle Scholar
• Gupta SC, Kismali G, and Aggarwal BB: Curcumin, a component of turmeric: from farm to pharmacy. Biofactors 39, 2–13, 2013. doi: 10.1002/biof.1079
   PubMed Web of Science ®Google Scholar
• Epstein J, Sanderson IR, and Macdonald TT: Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 103, 1545–1557, 2010. doi: 10.1017/s0007114509993667
   PubMed Web of Science ®Google Scholar
• Perrone D, Ardito F, Giannatempo G, Dioguardi M, Troiano G, et al.: Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med 10, 1615–1623, 2015. doi: 10.3892/etm.2015.2749
   PubMed Web of Science ®Google Scholar
• Villegas I, Sanchez-Fidalgo S, and Alarcon de la Lastra C: New mechanisms and therapeutic potential of curcumin for colorectal cancer. Mol Nutr Food Res 52, 1040–1061, 2008. doi: 10.1002/mnfr.200700280
   PubMed Web of Science ®Google Scholar
• Glienke W, Maute L, Wicht J, and Bergmann L: Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. Cancer Invest 28, 166–171, 2010. doi: 10.3109/07357900903287006
   PubMed Web of Science ®Google Scholar
• Leow PC, Tian Q, Ong ZY, Yang Z, and Ee PL: Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Invest New Drugs 28, 766–782, 2010. doi: 10.1007/s10637-009-9311-z
   PubMed Web of Science ®Google Scholar
• Fossey SL, Bear MD, Lin J, Li C, Schwartz EB, et al.: The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer 11, 112, 2011. doi: 10.1186/1471-2407-11-112
   PubMed Web of Science ®Google Scholar
• Wang L, Wang L, Song R, Shen Y, Sun Y, et al.: Targeting sarcoplasmic/endoplasmic reticulum Ca(2)+-ATPase 2 by curcumin induces ER stress-associated apoptosis for treating human liposarcoma. Mol Cancer Ther 10, 461–471, 2011. doi: 10.1158/1535-7163.mct-10-0812
   PubMed Web of Science ®Google Scholar
• Wei CC, Ball S, Lin L, Liu A, Fuchs JR, et al.: Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells. Int J Oncol 38, 279–285, 2011.
   PubMed Web of Science ®Google Scholar
• Vallianou NG, Evangelopoulos A, Schizas N, and Kazazis C: Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res 35, 645–651, 2015.
   PubMed Web of Science ®Google Scholar
• Fetoni AR, Paciello F, Mezzogori D, Rolesi R, Eramo SL, et al.: Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling. Br J Cancer 113, 1434–1444, 2015. doi: 10.1038/bjc.2015.359
   PubMed Web of Science ®Google Scholar
• Imbaby S, Ewais M, Essawy S, and Farag N: Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats. Hum Exp Toxicol 33, 800–813, 2014. doi: 10.1177/0960327114527628
   PubMed Web of Science ®Google Scholar
• Sadzuka Y, Nagamine M, Toyooka T, Ibuki Y, and Sonobe T: Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin. Int J Pharm 432, 42–49, 2012. doi: 10.1016/j.ijpharm.2012.04.062
   PubMed Web of Science ®Google Scholar
• Carlson LJ, Cote B, Alani AW, and Rao DA: Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity. J Pharm Sci 103, 2315–2322, 2014. doi: 10.1002/jps.24042
   PubMed Web of Science ®Google Scholar
• Swamy AV, Gulliaya S, Thippeswamy A, Koti BC, and Manjula DV: Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. Indian J Pharmacol 44, 73–77, 2012. doi: 10.4103/0253-7613.91871
   PubMed Web of Science ®Google Scholar
• Pramanik D, Campbell NR, Das S, Gupta S, Chenna V, et al.: A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget 3, 640–650, 2012. doi: 10.18632/oncotarget.543
   PubMed Web of Science ®Google Scholar
• Ostermann T, Raak C, and Bussing A: Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer 9, 451, 2009. doi: 10.1186/1471-2407-9-451
   PubMed Web of Science ®Google Scholar
• Nazaruk J and Orlikowski P: Phytochemical profile and therapeutic potential of Viscum album L. Nat Prod Res 30, 373–385, 2016. doi: 10.1080/14786419.2015.1022776
   PubMed Web of Science ®Google Scholar
• Melzer J, Iten F, Hostanska K, and Saller R: Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review. Forsch Komplementmed 16, 217–226, 2009. doi: 10.1159/000226249
   PubMedGoogle Scholar
• Delebinski CI, Twardziok M, Kleinsimon S, Hoff F, Mulsow K, et al.: A natural combination extract of viscum album L. containing both triterpene acids and lectins is highly effective against AML in vivo. PLoS One 10, e0133892, 2015. doi: 10.1371/journal.pone.0133892
   PubMed Web of Science ®Google Scholar
• Klingbeil MF, Xavier FC, Sardinha LR, Severino P, Mathor MB, et al.: Cytotoxic effects of mistletoe (Viscum album L.) in head and neck squamous cell carcinoma cell lines. Oncol Rep 30, 2316–2322, 2013. doi: 10.3892/or.2013.2732
   PubMed Web of Science ®Google Scholar
• Kelter G and Fiebig HH: Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe (Viscum album L.) extracts Iscador in vitro. Arzneimittelforschung 56, 435–440, 2006. doi: 10.1055/s-0031-1296809
   PubMed Web of Science ®Google Scholar
• Kelter G, Schierholz JM, Fischer IU, and Fiebig HH: Cytotoxic activity and absence of tumor growth stimulation of standardized mistletoe extracts in human tumor models in vitro. Anticancer Res 27, 223–233, 2007.
   PubMed Web of Science ®Google Scholar
• Han SY, Hong CE, Kim HG, and Lyu SY: Anti-cancer effects of enteric-coated polymers containing mistletoe lectin in murine melanoma cells in vitro and in vivo. Mol Cell Biochem 408, 73–87, 2015. doi: 10.1007/s11010-015-2484-1
   PubMed Web of Science ®Google Scholar
• Seifert G, Jesse P, Laengler A, Reindl T, Luth M, et al.: Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. Cancer Lett 264, 218–228, 2008. doi: 10.1016/j.canlet.2008.01.036
   PubMed Web of Science ®Google Scholar
• Troger W, Galun D, Reif M, Schumann A, Stankovic N, et al.: Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer 49, 3788–3797, 2013. doi: 10.1016/j.ejca.2013.06.043
   PubMed Web of Science ®Google Scholar
• Longhi A, Reif M, Mariani E, and Ferrari S: A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients. Evid Based Complement Alternat Med 2014, 210198, 2014. doi: 10.1155/2014/210198
   PubMed Web of Science ®Google Scholar
• Horneber MA, Bueschel G, Huber R, Linde K, and Rostock M: Mistletoe therapy in oncology. Cochrane Database Syst Rev CD003297, 2008. doi: 10.1002/14651858.CD003297.pub2
   PubMed Web of Science ®Google Scholar
• Stratford EW, Castro R, Daffinrud J, Skarn M, Lauvrak S, et al.: Characterization of liposarcoma cell lines for preclinical and biological studies. Sarcoma 2012, 148614, 2012. doi: 10.1155/2012/148614
   PubMedGoogle Scholar
• Aman P, Ron D, Mandahl N, Fioretos T, Heim S, et al.: Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer 5, 278–285, 1992.
   PubMed Web of Science ®Google Scholar
• Kawai A, Naito N, Yoshida A, Morimoto Y, Ouchida M, et al.: Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett 204, 105–113, 2004.
   PubMed Web of Science ®Google Scholar
• Xie Y, Skytting B, Nilsson G, Gasbarri A, Haslam K, et al.: SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation. Cancer Res 62, 3861–3867, 2002.
   PubMed Web of Science ®Google Scholar
• Becerikli M, Jacobsen F, Rittig A, Kohne W, Nambiar S, et al.: Growth rate of late passage sarcoma cells is independent of epigenetic events but dependent on the amount of chromosomal aberrations. Exp Cell Res 319, 1724–1731, 2013. doi: 10.1016/j.yexcr.2013.03.023
   PubMed Web of Science ®Google Scholar
• Hirsch T, von Peter S, Dubin G, Mittler D, Jacobsen F, et al.: Adenoviral gene delivery to primary human cutaneous cells and burn wounds. Mol Med 12, 199–207, 2006. doi: 10.2119/2006-00031.Hirsch
   PubMed Web of Science ®Google Scholar
• Steinstraesser L, Hauk J, Schubert C, Al-Benna S, Stricker I, et al.: Suppression of soft tissue sarcoma growth by a host defense-like lytic peptide. PLoS One 6, e18321, 2011. doi: 10.1371/journal.pone.0018321
   PubMed Web of Science ®Google Scholar
• Steinstraesser L, Schubert C, Hauk J, Becerikli M, Stricker I, et al.: Oncolytic designer host defense peptide suppresses growth of human liposarcoma. Int J Cancer 128, 2994–3004, 2011. doi: 10.1002/ijc.25627
   PubMed Web of Science ®Google Scholar
• Cen L, Hutzen B, Ball S, DeAngelis S, Chen CL, et al.: New structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cells. BMC Cancer 9, 99, 2009. doi: 10.1186/1471-2407-9-99
   PubMed Web of Science ®Google Scholar
• Jiang MC, Yang-Yen HF, Yen JJ, and Lin JK: Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer 26, 111–120, 1996. doi: 10.1080/01635589609514468
   PubMed Web of Science ®Google Scholar
• Liang T, Zhang X, Xue W, Zhao S, Zhang X, et al.: Curcumin induced human gastric cancer BGC-823 cells apoptosis by ROS-mediated ASK1-MKK4-JNK stress signaling pathway. Int J Mol Sci 15, 15754–15765, 2014. doi: 10.3390/ijms150915754
   PubMed Web of Science ®Google Scholar
• Kang JY, Huang H, and Zhu FQ: Effect of curcumin on growth and function of fibroblast in human hyperplastic scar. Zhongguo Zhong Xi Yi Jie He Za Zhi 29, 1100–1103, 2009.
   PubMedGoogle Scholar
• Urech K, Schaller G, and Jaggy C: Viscotoxins, mistletoe lectins and their isoforms in mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung 56, 428–434, 2006. doi: 10.1055/s-0031-1296808
   PubMed Web of Science ®Google Scholar
• Weissenstein U, Kunz M, Urech K, and Baumgartner S: Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Complement Altern Med 14, 6, 2014. doi: 10.1186/1472-6882-14-6
   PubMed Web of Science ®Google Scholar
• Eggenschwiler J, von Balthazar L, Stritt B, Pruntsch D, Ramos M, et al.: Mistletoe lectin is not the only cytotoxic component in fermented preparations of Viscum album from white fir (Abies pectinata). BMC Complement Altern Med 7, 14, 2007. doi: 10.1186/1472-6882-7-14
   PubMedGoogle Scholar
• Kovacs E, Link S, and Toffol-Schmidt U: Cytostatic and cytocidal effects of mistletoe (Viscum album L.) quercus extract Iscador. Arzneimittelforschung 56, 467–473, 2006. doi: 10.1055/s-0031-1296814
   PubMed Web of Science ®Google Scholar
• Podlech O, Harter PN, Mittelbronn M, Poschel S, and Naumann U: Fermented mistletoe extract as a multimodal antitumoral agent in gliomas. Evid Based Complement Alternat Med 2012, 501796, 2012. doi: 10.1155/2012/501796
   PubMed Web of Science ®Google Scholar
• Koval OA, Sakaeva GR, Fomin AS, Nushtaeva AA, Semenov DV, et al.: Sensitivity of endometrial cancer cells from primary human tumor samples to new potential anticancer peptide lactaptin. J Cancer Res Ther 11, 345–351, 2015. doi: 10.4103/0973-1482.157301
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang C, Wang W, Liu J, Liu Q, et al.: Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer. Sci Rep 6, 21225, 2016. doi: 10.1038/srep21225
   PubMed Web of Science ®Google Scholar
• Zhao X, Chen Q, Li Y, Tang H, Liu W, et al.: Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice. Eur J Pharm Biopharm 93, 27–36, 2015. doi: 10.1016/j.ejpb.2015.03.003
   PubMed Web of Science ®Google Scholar
• Meiyanto E, Putri DD, Susidarti RA, Murwanti R, Sardjiman  , et al.: Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. Asian Pac J Cancer Prev 15, 179–184, 2014.
   PubMedGoogle Scholar
• Duan J, Mansour HM, Zhang Y, Deng X, Chen Y, et al.: Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm 426, 193–201, 2012. doi: 10.1016/j.ijpharm.2012.01.020
   PubMed Web of Science ®Google Scholar
• Wang L, Wang W, Rui Z, and Zhou D: The effective combination therapy against human osteosarcoma: Doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system. Drug Deliv 23, 3200–3208, 2016. doi: 10.3109/10717544.2016.1162875
   Google Scholar
• Srdic-Rajic T, Tisma-Miletic N, Cavic M, Kanjer K, Savikin K, et al.: Sensitization of K562 leukemia cells to doxorubicin by the Viscum album extract. Phytother Res 30, 485–495, 2016. doi: 10.1002/ptr.5554
   PubMed Web of Science ®Google Scholar
• Hong CE, Park AK, and Lyu SY: Synergistic anticancer effects of lectin and doxorubicin in breast cancer cells. Mol Cell Biochem 394, 225–235, 2014. doi: 10.1007/s11010-014-2099-y
   PubMed Web of Science ®Google Scholar
• Siegle I, Fritz P, McClellan M, Gutzeit S, and Murdter TE: Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells. Anticancer Res 21, 2687–2691, 2001.
   PubMed Web of Science ®Google Scholar
• Troger W, Jezdic S, Zdrale Z, Tisma N, Hamre HJ, et al.: Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer (Auckl) 3, 35–45, 2009.
   PubMedGoogle Scholar
• Troger W, Zdrale Z, Stankovic N, and Matijasevic M: Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with Viscum album (L.) extract to chemotherapy alone. Breast Cancer (Auckl) 6, 173–180, 2012. doi: 10.4137/bcbcr.s10558
   PubMedGoogle Scholar
• Demirovic D, and Rattan SI: Curcumin induces stress response and hormetically modulates wound healing ability of human skin fibroblasts undergoing ageing in vitro. Biogerontology 12, 437–444, 2011. doi: 10.1007/s10522-011-9326-7
   PubMed Web of Science ®Google Scholar
• Grabowska W, Kucharewicz K, Wnuk M, Lewinska A, Suszek M, et al.: Curcumin induces senescence of primary human cells building the vasculature in a DNA damage and ATM-independent manner. Age (Dordr) 37, 9744, 2015. doi: 10.1007/s11357-014-9744-y
   PubMed Web of Science ®Google Scholar
• Grabowska W, Suszek M, Wnuk M, Lewinska A, Wasiak E, et al.: Curcumin elevates sirtuin level but does not postpone in vitro senescence of human cells building the vasculature. Oncotarget 7, 19201–19213, 2016. doi: 10.18632/oncotarget.8450
   PubMed Web of Science ®Google Scholar
• Mosieniak G, Sliwinska MA, Przybylska D, Grabowska W, Sunderland P, et al.: Curcumin-treated cancer cells show mitotic disturbances leading to growth arrest and induction of senescence phenotype. Int J Biochem Cell Biol 74, 33–43, 2016. doi: 10.1016/j.biocel.2016.02.014
   Google Scholar
• Lewinska A, Wnuk M, Grabowska W, Zabek T, Semik E, et al.: Curcumin induces oxidation-dependent cell cycle arrest mediated by SIRT7 inhibition of rDNA transcription in human aortic smooth muscle cells. Toxicol Lett 233, 227–238, 2015. doi: 10.1016/j.toxlet.2015.01.019
   PubMed Web of Science ®Google Scholar
• Harati K, Chromik AM, Bulut D, Goertz O, Hahn S, et al.: TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in HT1080 human fibrosarcoma cells. Anticancer Res 32, 2967–2984, 2012.
   PubMed Web of Science ®Google Scholar
• Karlisch C, Harati K, Chromik AM, Bulut D, Klein-Hitpass L, et al.: Effects of TRAIL and taurolidine on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma. Int J Oncol 42, 945–956, 2013. doi: 10.3892/ijo.2013.1772
   PubMed Web of Science ®Google Scholar
• Vlenterie M, Litiere S, Rizzo E, Marreaud S, Judson I, et al.: Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. Eur J Cancer 58, 62–72, 2016. doi: 10.1016/j.ejca.2016.02.002
   PubMed Web of Science ®Google Scholar
• Italiano A, Toulmonde M, Cioffi A, Penel N, Isambert N, et al.: Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol 23, 1601–1607, 2012. doi: 10.1093/annonc/mdr485
   PubMed Web of Science ®Google Scholar
• Italiano A, Garbay D, Cioffi A, Maki RG, and Bui B: Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. Ann Oncol 23, 2205–2206, 2012. doi: 10.1093/annonc/mds219
   PubMed Web of Science ®Google Scholar
• Jones RL, Fisher C, Al-Muderis O, and Judson IR: Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 41, 2853–2860, 2005. doi: 10.1016/j.ejca.2005.07.023
   PubMed Web of Science ®Google Scholar
• Patel SR, Burgess MA, Plager C, Papadopoulos NE, Linke KA, et al.: Myxoid liposarcoma. Experience with chemotherapy. Cancer 74, 1265–1269, 1994.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21, 2895–2900, 2001.
   PubMed Web of Science ®Google Scholar
• Burgos-Moron E, Calderon-Montano JM, Salvador J, Robles A, and Lopez-Lazaro M: The dark side of curcumin. Int J Cancer 126, 1771–1775, 2010. doi: 10.1002/ijc.24967
   PubMed Web of Science ®Google Scholar
• Zhongfa L, Chiu M, Wang J, Chen W, Yen W, et al.: Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemother Pharmacol 69, 679–689, 2012. doi: 10.1007/s00280-011-1749-y
   PubMed Web of Science ®Google Scholar
• Cui J, Yu B, Zhao Y, Zhu W, Li H, et al.: Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm 371, 148–155, 2009. doi: 10.1016/j.ijpharm.2008.12.009
   PubMed Web of Science ®Google Scholar
• Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, et al.: Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem 58, 2095–2099, 2010. doi: 10.1021/jf9024807
   PubMed Web of Science ®Google Scholar
• Kuriakose MA, Ramdas K, Dey B, Iyer S, Rajan G, et al.: A randomized double-blind placebo-controlled phase IIB trial of curcumin in oral leukoplakia. Cancer Prev Res (Phila) 9, 683–691, 2016. doi: 10.1158/1940-6207.capr-15-0390
   PubMed Web of Science ®Google Scholar
• Klickovic U, Doberer D, Gouya G, Aschauer S, Weisshaar S, et al.: Human pharmacokinetics of high dose oral curcumin and its effect on heme oxygenase-1 expression in healthy male subjects. Biomed Res Int 2014, 458592, 2014. doi: 10.1155/2014/458592
   PubMed Web of Science ®Google Scholar
• Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, et al.: Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 4, 354–364, 2011. doi: 10.1158/1940-6207.capr-10-0098
   PubMed Web of Science ®Google Scholar
• Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, et al.: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10, 6847–6854, 2004. doi: 10.1158/1078-0432.ccr-04-0744
   PubMed Web of Science ®Google Scholar
• Goodpasture CE, and Arrighi FE: Effects of food seasonings on the cell cycle and chromosome morphology of mammalian cells in vitro with special reference to turmeric. Food Cosmet Toxicol 14, 9–14, 1976.
   PubMedGoogle Scholar
• Sakano K, and Kawanishi S: Metal-mediated DNA damage induced by curcumin in the presence of human cytochrome P450 isozymes. Arch Biochem Biophys 405, 223–230, 2002.
   PubMed Web of Science ®Google Scholar
• Cao J, Jia L, Zhou HM, Liu Y, and Zhong LF: Mitochondrial and nuclear DNA damage induced by curcumin in human hepatoma G2 cells. Toxicol Sci 91, 476–483, 2006. doi: 10.1093/toxsci/kfj153
   PubMed Web of Science ®Google Scholar
• Bock PR, Friedel WE, Hanisch J, Karasmann M, and Schneider B: Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittelforschung 54, 456–466, 2004. doi: 10.1055/s-0031-1296999
   PubMed Web of Science ®Google Scholar
• Steele ML, Axtner J, Happe A, Kroz M, Matthes H, et al.: Adverse drug reactions and expected effects to therapy with subcutaneous mistletoe extracts (Viscum album L.) in cancer patients. Evid Based Complement Alternat Med 2014, 724258, 2014. doi: 10.1155/2014/724258
   PubMed Web of Science ®Google Scholar
• Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, et al.: Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24, 303–309, 2004.
   PubMed Web of Science ®Google Scholar